BRCA1 and neoplasm: The large magnitude of the treatment effect in patients with somatic BRCA1/2 mutations (PFS HR 0.23, 95% CI 0.04-1.12) was consistent with that observed in patients identified based on tumor analysis as having germline BRCA1/2 mutations (PFS HR 0.17, 95% CI 0.09-0.34; Figure 2 and Table 2), as well as that previously reported in all patients with BRCA1/2 mutations [10].